Bronchiolitis obliterans syndrome is a serious lung condition affecting the smallest airways, requiring careful medical attention to slow its progression and maintain quality of life for those affected.

Managing a Complex Lung Condition: Goals and Approaches

The treatment of bronchiolitis obliterans syndrome focuses primarily on slowing down the progressive damage to the lungs and managing symptoms that impact daily life. This condition, which causes permanent narrowing and scarring of the tiny airways called bronchioles, cannot be reversed once it develops, making early intervention and careful monitoring essential for the best possible outcomes.^[1]

Treatment strategies vary significantly depending on what caused the condition in the first place. For people who developed bronchiolitis obliterans syndrome after receiving a lung or bone marrow transplant, the approach differs from those who developed it after breathing in toxic chemicals or following a severe respiratory infection. The stage of the disease also matters greatly—some individuals may have mild symptoms that progress slowly, while others experience rapid decline in lung function requiring more aggressive intervention.^[3]

Medical teams use established treatment guidelines approved by professional medical societies, but they also recognize that each patient’s situation is unique. This means treatment plans must be personalized, taking into account not just the severity of lung damage but also other health conditions, age, and individual circumstances. Beyond standard treatments used for years, researchers continue exploring new therapies through clinical trials, offering hope for better options in the future.^[1]

The overarching goal is to preserve as much lung function as possible, reduce uncomfortable symptoms like shortness of breath and coughing, prevent complications such as respiratory infections, and help people maintain their independence and ability to participate in daily activities for as long as possible.^[5]

Standard Treatment Approaches

The cornerstone of treating bronchiolitis obliterans syndrome involves medications that reduce inflammation in the airways. Corticosteroids, which are powerful anti-inflammatory drugs, represent the most commonly used first-line treatment. These medications work by dampening the immune system’s overactive response that contributes to airway damage and scarring. Doctors may prescribe corticosteroids in different ways—some patients receive high doses given intravenously in cycles called “pulse therapy,” repeated monthly or at other intervals, while others take daily oral tablets or use inhaled versions that deliver the medication directly to the lungs.^[5]

For patients who developed bronchiolitis obliterans syndrome after an organ transplant, which medical professionals consider a form of chronic rejection, treatment becomes more complex. These individuals typically already take immunosuppressive medications to prevent their body from rejecting the transplanted organ. When bronchiolitis obliterans syndrome develops despite these drugs, doctors may need to adjust the doses or add different immunosuppressive agents to better control the rejection process. Common immunosuppressive drugs used include tacrolimus, cyclosporine, azathioprine, and mycophenolate mofetil.^[10]

Another medication showing promise is azithromycin, an antibiotic that surprisingly has anti-inflammatory properties beyond its ability to fight bacteria. Studies have found that some patients taking azithromycin regularly experience stabilization of their lung function, though researchers don’t fully understand why this occurs. The drug may reduce inflammation through mechanisms unrelated to killing bacteria. Doctors often prescribe it three times per week as a long-term maintenance therapy.^[5]

Montelukast, a medication originally developed for asthma, also finds use in some treatment plans. This drug blocks certain inflammatory chemicals in the body called leukotrienes. While not effective for everyone, some patients benefit from adding montelukast to their treatment regimen, particularly when combined with other anti-inflammatory therapies.^[5]

The duration of treatment depends heavily on the underlying cause and how the patient responds. For those with transplant-related bronchiolitis obliterans syndrome, treatment continues indefinitely because stopping immunosuppressive medications could trigger acute rejection. For other causes, doctors carefully monitor lung function tests and symptoms to determine how long medications should continue.^[1]

Beyond medications targeting inflammation, patients often need supportive treatments to manage symptoms and maintain function. Many people with bronchiolitis obliterans syndrome develop low oxygen levels in their blood, requiring supplemental oxygen therapy at home. This might mean using oxygen only during physical activity or sleep initially, but some patients eventually need continuous oxygen throughout the day and night. Oxygen therapy helps prevent strain on the heart and allows people to remain more active despite damaged lungs.^[8]

Pulmonary rehabilitation programs offer significant benefits for many patients. These structured programs combine supervised exercise training, breathing techniques, nutritional counseling, and education about lung disease. Physical therapists and respiratory therapists work with patients to improve exercise tolerance, strengthen breathing muscles, and learn strategies for conserving energy during daily activities. While rehabilitation doesn’t reverse lung damage, it helps people function better with the lung capacity they have.^[8]

Preventing respiratory infections becomes critically important, as even common colds or flu can cause serious complications in people with already-compromised lungs. Doctors strongly recommend annual influenza vaccines, pneumococcal vaccines to prevent bacterial pneumonia, and staying current with other immunizations. Some patients receive prophylactic antibiotics—medications taken regularly to prevent infections before they start—particularly during cold and flu season.^[7]

For patients with severe, progressive disease who don’t respond adequately to medical treatment, lung transplantation may be considered. This major surgical procedure replaces the damaged lungs with healthy donor lungs. However, transplantation carries its own significant risks and requires lifelong immunosuppressive therapy. Additionally, the ironic challenge exists that bronchiolitis obliterans syndrome itself represents the most common form of chronic rejection after lung transplantation, meaning the condition can potentially recur in the new lungs.^[1]

Emerging Treatments in Clinical Research

Researchers around the world continue investigating new approaches to treat bronchiolitis obliterans syndrome, with numerous clinical trials testing innovative therapies that target different aspects of the disease process. These studies aim to find treatments that more effectively slow or stop the progressive lung damage while causing fewer side effects than current options.^[10]

One promising area involves newer immunosuppressive medications with more selective mechanisms of action. Traditional immunosuppressive drugs broadly suppress the entire immune system, increasing infection risk. Newer agents under investigation work more precisely, targeting specific immune cells or pathways involved in chronic rejection while leaving other protective immune functions intact. Clinical trials are testing drugs like everolimus and sirolimus, which belong to a class called mTOR inhibitors. These medications interfere with signals that promote inflammation and scar tissue formation. Early research suggests they might help stabilize lung function in some transplant recipients with bronchiolitis obliterans syndrome.^[10]

Another innovative approach involves extracorporeal photopheresis, a procedure where blood is removed from the patient, treated outside the body with ultraviolet light in the presence of a light-sensitive medication, and then returned to the patient. This treatment modifies certain immune cells in ways that may reduce their tendency to attack transplanted organs. Several clinical trials have evaluated extracorporeal photopheresis for treating bronchiolitis obliterans syndrome after lung transplantation, with some studies showing stabilization or even slight improvement in lung function for certain patients. The procedure typically requires multiple sessions over weeks or months. Research continues to determine which patients benefit most and the optimal treatment schedule.^[10]

Monoclonal antibodies represent another frontier in treatment research. These laboratory-made proteins target very specific molecules involved in inflammation and immune responses. Clinical investigators are studying various monoclonal antibodies for their potential to prevent or treat chronic rejection. Some target proteins that help activate immune cells, while others block inflammatory signals. These therapies are still largely in Phase I (testing safety in small groups of patients) and Phase II (determining whether they work and at what doses) clinical trials, with results not yet definitive enough for routine clinical use.^[10]

Pirfenidone and nintedanib, drugs approved for treating another lung scarring disease called pulmonary fibrosis, are being investigated for bronchiolitis obliterans syndrome. These medications work by interfering with cellular processes that lead to scarring and thickening of lung tissue. Since scar tissue formation plays a major role in bronchiolitis obliterans syndrome, researchers hypothesize these anti-fibrotic agents might slow disease progression. Several clinical trials are currently underway, primarily in Phase II, testing whether these drugs can preserve lung function in transplant recipients developing chronic rejection. Early results show mixed outcomes, with some patients experiencing slowed decline in lung function but others showing no benefit.^[10]

Gene therapy approaches, though still in very early research stages, offer theoretical promise for the future. Scientists are exploring whether delivering specific genes to lung cells could reduce inflammation, prevent scar tissue formation, or help repair damaged airways. This research remains largely in laboratory and animal testing phases, with human clinical trials likely years away. The technical challenges of safely and effectively delivering genetic material specifically to small airways make this a particularly difficult area of investigation.^[10]

Stem cell therapies represent another area of active investigation. Researchers are studying whether certain types of stem cells, particularly those called mesenchymal stem cells, might help repair damaged lung tissue or reduce inflammation when given intravenously or directly into the lungs. Some early Phase I trials have tested safety in small numbers of patients with chronic lung diseases including bronchiolitis obliterans syndrome. While initial safety data appears encouraging, much more research is needed to determine whether these approaches actually improve lung function or patient outcomes.^[10]

Clinical trials for bronchiolitis obliterans syndrome are conducted at major transplant centers and research hospitals across the United States, Europe, and other regions. Patients interested in participating can discuss options with their pulmonologists or transplant teams, who can help determine eligibility based on specific trial criteria. Factors affecting eligibility typically include the cause of bronchiolitis obliterans syndrome, severity of lung function decline, time since diagnosis, and other medical conditions. Many trials specifically focus on transplant recipients since this represents the most common patient population affected by the condition.^[10]

Researchers also investigate better ways to detect bronchiolitis obliterans syndrome earlier, before significant permanent damage occurs. Studies are evaluating blood tests measuring specific proteins or immune markers that might signal developing chronic rejection before lung function tests show decline. Earlier detection could allow treatment to begin sooner, potentially preventing more severe lung damage. These diagnostic research efforts run parallel to treatment studies, with both aimed at improving outcomes for people with this challenging condition.^[20]

Most Common Treatment Methods

• Anti-inflammatory medications
  • Corticosteroids administered orally, intravenously, or through inhalation to reduce airway inflammation
  • High-dose pulse steroid therapy given at regular intervals
  • Azithromycin antibiotic with anti-inflammatory properties, typically given three times weekly
  • Montelukast to block inflammatory leukotrienes
• Immunosuppressive therapy
  • Adjustment of existing immunosuppression in transplant recipients
  • Medications such as tacrolimus, cyclosporine, azathioprine, and mycophenolate mofetil
  • Newer agents like mTOR inhibitors (everolimus, sirolimus) being studied in clinical trials
• Supportive respiratory care
  • Supplemental oxygen therapy for patients with low blood oxygen levels
  • Pulmonary rehabilitation programs combining exercise training and breathing techniques
  • Bronchodilator medications to help open airways
• Infection prevention measures
  • Annual influenza vaccination
  • Pneumococcal vaccination
  • Prophylactic antibiotics in some cases
  • Avoiding exposure to respiratory illnesses
• Advanced interventions
  • Extracorporeal photopheresis for transplant-related cases
  • Lung transplantation for severe, progressive disease
  • Anti-fibrotic medications (pirfenidone, nintedanib) under investigation in clinical trials
• Experimental therapies in clinical trials
  • Monoclonal antibody treatments targeting specific immune pathways
  • Stem cell therapies being evaluated for safety and potential benefit
  • Gene therapy approaches in early research stages